Evidence map›Paper›PMID 27565280›Full record

ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis.

Shi-Yi Wang, Sylvia H Hsu, Cary P Gross, Tara Sanft, Amy J Davidoff, Xiaomei Ma, James B Yu

Open access · greenAbstract read
In one paragraph

Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. A Systematic Literature Review of Health Utility Values in Breast Cancer.Medical decision making : an international journal of the Society for Medical Decision Making · 2022
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Trends in health-related quality of life of female breast cancer survivors using the Medical Expenditure Panel Survey (MEPS), 2008-2016.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Article
  13. Exploring health-related quality of life among non-Hodgkin's lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  14. Article
  15. Article
  16. A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients' Experience.International journal of environmental research and public health · 2020
    Article
  17. Article
  18. Article
  19. Psychotropic polypharmacy and its association with health-related quality of life among cancer survivors in the USA: a population-level analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Shi-Yi WangCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT, USA. Electronic address: shiyi.wang@yale.edu.
Sylvia H HsuDepartment of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT, USA; Schulich School of Business, York University, Toronto, Ontario, Canada.
Cary P GrossCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Section of General Internal Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Tara SanftCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Amy J DavidoffCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT, USA.
Xiaomei MaCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT, USA.
James B YuCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
Yale University · USYale Cancer Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Institutional Career Development CoreKL2TR001862 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$12.2M
Development and Evaluation of a Decision Analysis Based Decision AidK01HS023900 · AHRQ · YALE UNIVERSITY · PI WANG, SHIYI · 2015 to 2019
$754k
AHRQ HHS K01 HS023900NCATS NIH HHS KL2 TR001862NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016359
6 · The paper itself

Abstract

objectivesTo examine the association between time since cancer diagnosis and health-related quality of life (HRQOL) among cancer survivors in remission.

methodsAnalyzing data from 3,610 cancer survivors and 59,539 individuals without cancer in the Medical Expenditure Panel Survey, we examined the relationship between time since cancer diagnosis and HRQOL, taking remission status into account and controlling for patients' demographic characteristics and comorbidities. HRQOL measurements included the six-dimensional health state short form (derived from 36-item short form health survey) (SF-6D) utility scores, the physical component summary score, and the mental component summary score.

resultsThe relationship between time since cancer diagnosis and HRQOL varied substantially across cancer types. Compared with individuals without cancer, survivors of breast, prostate, or poor-prognosis cancer had statistically lower SF-6D scores within 2 years of diagnosis (-0.044, -0.062, and -0.088, respectively). Breast cancer survivors had SF-6D scores similar to those of individuals without cancer after 2 years, as did patients with poor-prognosis cancer after 5 years. Nevertheless, even after a period of 10 years, survivors of prostate or cervical cancer had a lower level of SF-6D scores (-0.027 and -0.042, respectively). The comparisons of physical health between cancer survivors and individuals without cancer were similar to those of SF-6D. In contrast, most cancer survivors did not experience poorer mental health; survivors of prostate or cervical cancer, however, had lower mental component summary scores after 10 years of diagnosis.

conclusionsThe level of HRQOL among cancer survivors depends on time since cancer diagnosis and cancer type. Some cancer survivors have lower HRQOL after a decade of diagnosis, even in remission.

Indexed as

Disease-Free SurvivalHealth StatusQuality of LifeAdolescentAdultAgedAged, 80 and overFemaleHealth SurveysHumansMaleMiddle AgedNeoplasmsTime FactorsYoung Adultcancer survivorshealth-related quality of life (HRQOL)SF-6Dtime-sensitive differences

Identifiers

PMID27565280
PMCPMC5002308
OpenAlexW2316887046

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.